Company intelligence / Profile preview

AustinPx

Ownership: Private
Employees: ~46
Development stage: Commercial

Overview

AustinPx is an active, award-winning contract development and manufacturing organization specializing in oral dosage forms of small molecules. The company is recognized for its expertise in bioavailability enhancement—especially using its proprietary KinetiSol™ amorphous solid dispersion technology—and offers services from preclinical through Phase II clinical development. It has received industry innovation awards in 2024 for its technologies. Clinical results are those of client programs; no direct pipeline data available as it is a service provider.

Modalities: Small moleculeAmorphous solid dispersion (ASD) technology-based formulations
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on AustinPx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AustinPx.

Explore the full profile